Exclusive access
From April 3 to 8, 2027, WEDC will lead a Global Trade Mission to France, focusing on helping participants to connect with prospective partners, customers, and distributors at the BIO-Europe spring trade show.
Meetings will be focused in and around the trade show venue in Lyon, but since the event draws attendees from all over the world, participants can expect opportunities to make connections with potential partners from across Europe and beyond. Since the trade show serves as a central gathering place for industry companies, you’ll be able to hold many meetings in a compressed amount of time, rather than traveling around to multiple locations.
Companies especially urged to consider attending include:
- Drug discovery companies
- Therapeutics developers
- Cell and gene therapy companies
- Oncology companies
- Rare disease companies
- Platform technology companies
Business connections
The BIO-Europe Spring 2027 trade show brings together biotechnology, pharmaceutical, and life sciences organizations from across Europe, providing Wisconsin companies with access to a broad range of potential customers, strategic partners, investors, and commercialization opportunities in markets with strong research and development investment and healthcare innovation ecosystems.
Despite global economic and political uncertainty, Europe remains one of the world’s leading hubs for biotechnology investment, pharmaceutical development, licensing, and cross-border collaboration, making this trade show a key opportunity for partnership and business development discussions.
Explore export opportunities in Europe’s biohealth sector
The European Union is one of the world’s largest and most sophisticated life sciences markets, representing more than 440 million consumers across 27 member states. Europe continues to prioritize life sciences innovation, healthcare resilience, and supply chain security following the COVID-19 pandemic, leading to ongoing investment in biotechnology, advanced manufacturing, diagnostics, and pharmaceutical production.
The region offers a highly skilled workforce, world-class research institutions, and strong healthcare systems—plus significant investment in biotechnology, pharmaceuticals, medical technology, and digital health innovation. The EU also provides companies with access to a large, integrated market through harmonized regulations and extensive cross-border business opportunities.
Geopolitical developments and global supply chain disruptions have increased interest in strategic partnerships, regional manufacturing capacity, and diversified sourcing across the life sciences sector. This has created new opportunities for companies offering innovative technologies, manufacturing capabilities, and research collaborations.

